TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12205786

Group type: EXPERIMENTAL
Intervention: Racecadotril and rehydration
Number of subjects: 166

Group type: COMPARATOR
Intervention: Rehydration alone
Number of subjects: 166
Study: 9614617

Group type: EXPERIMENTAL
Intervention: Lispro insulin (LP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Regular insulin (ACT)
Number of subjects: 39
Study: 9098283

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 41
Study: 2559509

Group type: EXPERIMENTAL
Intervention: Fortnightly chemoprophylaxis with Maloprim
Number of subjects: 750

Group type: COMPARATOR
Intervention: Control group (not receiving Maloprim)
Number of subjects: 750
Study: 845144

Group type: EXPERIMENTAL
Intervention: Self-instructional units for visual imagery training
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no imagery training)
Number of subjects: 110
Study: 31694484

Group type: EXPERIMENTAL
Intervention: Face-to-face programming of hearing aids
Number of subjects: 52

Group type: COMPARATOR
Intervention: Remote programming of hearing aids
Number of subjects: 52
Study: 31386217

Group type: EXPERIMENTAL
Intervention: Early pubertal maturation
Number of subjects: 2991

Group type: COMPARATOR
Intervention: Overweightness and early pubertal maturation
Number of subjects: 2991
Study: 31181017

Group type: EXPERIMENTAL
Intervention: Domperidone 0.25 mg/kg with oral rehydration therapy (ORT)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo with oral rehydration therapy (ORT)
Number of subjects: 292
Study: 28591564

Group type: EXPERIMENTAL
Intervention: Model osteoarthritis consultation (MOAC) in intervention practices
Number of subjects: 1960

Group type: COMPARATOR
Intervention: Usual care in control practices
Number of subjects: 1960
Study: 26025570

Group type: EXPERIMENTAL
Intervention: Intervention not specified (part of a randomized trial)
Number of subjects: 729
Study: 23092529

Group type: EXPERIMENTAL
Intervention: Moxifloxacin hydrochloride
Number of subjects: 124

Group type: COMPARATOR
Intervention: Polymyxin B‐trimethoprim
Number of subjects: 124
Study: 24653477

Group type: EXPERIMENTAL
Intervention: Dignity therapy plus standard care
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard care only (control group)
Number of subjects: 45
Study: 19861324

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 4648

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 4648
Study: 16829488

Group type: EXPERIMENTAL
Intervention: Short Response Signal Delay (RSD) group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long Response Signal Delay (RSD) group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conceptual cue generation procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anagram generation procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2250-ms RSD
Number of subjects: 0
Study: 15283941

Group type: EXPERIMENTAL
Intervention: Oral hormone replacement therapy (estradiol 2 mg/norethisterone acetate 1 mg-Kliogest)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 11007080

Group type: EXPERIMENTAL
Intervention: Percutaneous dilatational tracheostomy (PDT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard tracheostomy (ST)
Number of subjects: 0
Study: 9068313

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone
Number of subjects: 5

Group type: COMPARATOR
Intervention: Historical group (control)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 5
Study: 8313746

Group type: EXPERIMENTAL
Intervention: Nylestriol 2 mg/2 weeks (Group A)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Nylestriol 1 mg/2 weeks (Group B)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 283
Study: 3525424

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Labetalol (100 mg)
Number of subjects: 21
Study: 31077891

Group type: EXPERIMENTAL
Intervention: Biportal endoscopic lumbar decompressive laminectomy (BE‐D)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Mini-open microscopic lumbar decompressive laminectomy (MI‐D)
Number of subjects: 64
Study: 29031768

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation therapy (100% oxygen in hyperbaric conditions)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Air (control group)
Number of subjects: 109
Study: 27480410

Group type: EXPERIMENTAL
Intervention: Plasma-Lyte A (PLA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.9 % sodium chloride (NaCl)
Number of subjects: 100
Study: 24667749

Group type: EXPERIMENTAL
Intervention: 2.5% alginate CM
Number of subjects: 24

Group type: COMPARATOR
Intervention: 1.25% alginate CM
Number of subjects: 24
Study: 22757595

Group type: EXPERIMENTAL
Intervention: Resourcefulness Training (RT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Diversionary Activities (DA)
Number of subjects: 38
Study: 20399113

Group type: EXPERIMENTAL
Intervention: Bilateral femoral puncture
Number of subjects: 57

Group type: COMPARATOR
Intervention: Unilateral femoral puncture
Number of subjects: 57
Study: 18942274

Group type: EXPERIMENTAL
Intervention: Enhanced decision aid
Number of subjects: 87

Group type: COMPARATOR
Intervention: Usual care decision aid
Number of subjects: 87
Study: 15230823

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11824669

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg the evening before and 40 mg the morning of surgery)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no atorvastatin)
Number of subjects: 20
Study: 9572206

Group type: EXPERIMENTAL
Intervention: Telephone calls from registered nurses, one or two times weekly from 24 weeks' through 37 weeks' gestation
Number of subjects: 1554

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1554

Group type: EXPERIMENTAL
Intervention: Telephone calls from registered nurses, one or two times weekly from 24 weeks' through 37 weeks' gestation in low-income black women 19 years of age and older
Number of subjects: 1554

Group type: COMPARATOR
Intervention: Control group (no intervention) in low-income black women 19 years of age and older
Number of subjects: 1554
Study: 8068791

Group type: EXPERIMENTAL
Intervention: Warning letters threatening prosecution
Number of subjects: 255

Group type: COMPARATOR
Intervention: No warning letters
Number of subjects: 255
Study: 2784322

Group type: EXPERIMENTAL
Intervention: cyclosporin A
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 57048

Group type: EXPERIMENTAL
Intervention: Attention directed to tones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tone intensity effects on N1 and P2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined N1-P2 amplitude measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interstimulus intervals based on prior intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attention to tones
Number of subjects: 0
Study: 31745987

Group type: EXPERIMENTAL
Intervention: Potassium citrate supplementation
Number of subjects: 51

Group type: COMPARATOR
Intervention: No potassium citrate supplementation (Control)
Number of subjects: 51
Study: 31332045

Group type: EXPERIMENTAL
Intervention: SoC+ECP
Number of subjects: 60

Group type: COMPARATOR
Intervention: SoC
Number of subjects: 60
Study: 27429228

Group type: EXPERIMENTAL
Intervention: Manuka honey applied twice daily
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (Vaseline applied 4 times a day)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Manuka honey
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (Vaseline)
Number of subjects: 55
Study: 25030325

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg
Number of subjects: 67
Study: 23072780

Group type: EXPERIMENTAL
Intervention: Irradiated white blood cell transfusions
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Unirradiated white blood cell transfusions
Number of subjects: 108
Study: 21466650

Group type: EXPERIMENTAL
Intervention: Reduced-dose tacrolimus with mycophenolate mofetil
Number of subjects: 195

Group type: COMPARATOR
Intervention: Standard-dose tacrolimus
Number of subjects: 195
Study: 17428556

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dobutamin
Number of subjects: 0
Study: 16701193

Group type: EXPERIMENTAL
Intervention: Epidural with bupivacaine 0.1% and fentanyl 3mug/ml
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Continuous peripheral nerve block (CPNB) with ropivacaine 0.2%
Number of subjects: 27

Group type: COMPARATOR
Intervention: Patient controlled analgesia (PCA) with i.v. morphine
Number of subjects: 27
Study: 12887380

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 122

Group type: COMPARATOR
Intervention: IRM
Number of subjects: 122
Study: 11468003

Group type: EXPERIMENTAL
Intervention: Modified Greiff/Grunberg method
Number of subjects: 24

Group type: COMPARATOR
Intervention: Naclerio method
Number of subjects: 24
Study: 9009533

Group type: EXPERIMENTAL
Intervention: Gluma primer only (group 1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cleanser followed by primer (group 2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cleanser followed by primer and sealer (group 3)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (group 4)
Number of subjects: 15
Study: 8289749

Group type: EXPERIMENTAL
Intervention: Halothane (0.4 to 0.6%)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Isoflurane (0.6 to 0.8%)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Enflurane (0.8 to 1%)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Halothane, Isoflurane, Enflurane
Number of subjects: 169
Study: 3083146

Group type: EXPERIMENTAL
Intervention: Short-term MF chemotherapy (mitomycin C, 0.04 mg/kg + 5-fluorouracil, 5.0 mg/kg X 6, IVr)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-term carmofur chemotherapy (Mifurol, 6-12 mg/kg/day over 12 weeks, PO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carmofur maintenance therapy
Number of subjects: 0
Study: 30171784

Group type: EXPERIMENTAL
Intervention: PPC (personal protective clothing)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: SCBA (full self‐contained breathing apparatus)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: SCBAc (only the cylinder of the self‐contained breathing apparatus)
Number of subjects: 34
Study: 27494299

Group type: EXPERIMENTAL
Intervention: Tafamidis (20 mg once daily)
Number of subjects: 0
Study: 24818952

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 10074

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 10074
Study: 22402737

Group type: EXPERIMENTAL
Intervention: Weight loss of at least 5% of baseline weight
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Weight loss of 5-10% of baseline weight
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Weight loss of >10% of baseline weight
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: No weight loss
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Overall weight loss effect
Number of subjects: 383
Study: 19782346

Group type: EXPERIMENTAL
Intervention: 250 microg recombinant hCG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 500 microg recombinant hCG
Number of subjects: 0
Study: 18443051

Group type: EXPERIMENTAL
Intervention: Anterior approach trapeziectomy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Posterior approach trapeziectomy
Number of subjects: 41
Study: 15832879

Group type: EXPERIMENTAL
Intervention: Intervention developed specifically for Latino gay and bisexual men, based on empowerment theory.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 180
Study: 12574571

Group type: EXPERIMENTAL
Intervention: Early Supported Discharge (ESD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 0
Study: 10579057

Group type: EXPERIMENTAL
Intervention: Eradication therapy consisting of metronidazole, bismuth subcitrate, and amoxicillin
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 8930145

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (20 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (30 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 10
Study: 1811040

Group type: EXPERIMENTAL
Intervention: Kurer Fin Lock Anchor
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Radix Anchor
Number of subjects: 25

Group type: COMPARATOR
Intervention: Para-Post Plus (control post)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Flexi-Post
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Vlock post
Number of subjects: 25
Study: 3912355

Group type: EXPERIMENTAL
Intervention: 34.5 Gy of radiotherapy (in 3 weeks) followed by surgery
Number of subjects: 466

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 466
Study: 31898551

Group type: EXPERIMENTAL
Intervention: Cognitive ergonomics intervention
Number of subjects: 1169

Group type: COMPARATOR
Intervention: Active control group (recovery supporting)
Number of subjects: 1169

Group type: COMPARATOR
Intervention: Passive control group (no intervention)
Number of subjects: 1169
Study: 29994874

Group type: EXPERIMENTAL
Intervention: paritaprevir/ombitasvir/ritonavir/dasabuvir/ribavirin (RBV) for 12 weeks
Number of subjects: 96

Group type: COMPARATOR
Intervention: ledipasvir/sofosbuvir (SOF)/RBV for 12 weeks
Number of subjects: 96
Study: 26771445

Group type: EXPERIMENTAL
Intervention: Febuxostat (80 mg QD)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Allopurinol (300 mg QD)
Number of subjects: 109
Study: 25376884

Group type: EXPERIMENTAL
Intervention: Whey-protein drink (20 g daily plus 20 g after each PRT session) and vitamin D supplements (2000 IU/day)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) based on the Lift for Life® programme
Number of subjects: 200

Group type: COMPARATOR
Intervention: No additional powder and supplements (control group)
Number of subjects: 200
Study: 22497897

Group type: EXPERIMENTAL
Intervention: Letter fluency test
Number of subjects: 0
Study: 20545392

Group type: EXPERIMENTAL
Intervention: Codeine 30 mg b.i.d. (0900 and 1300)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo b.i.d.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Codeine 30 mg b.i.d.
Number of subjects: 12
Study: 18635428

Group type: COMPARATOR
Intervention: Low-fat diet, restricted-calorie
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Mediterranean diet, restricted-calorie
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet, non-restricted-calorie
Number of subjects: 322
Study: 17207282

Group type: EXPERIMENTAL
Intervention: Amaranth oil application
Number of subjects: 0
Study: 14973337

Group type: EXPERIMENTAL
Intervention: Bilateral arm raising and lowering at 3 different speeds
Number of subjects: 8
Study: 11203744

Group type: EXPERIMENTAL
Intervention: Menstrual cycle phases (menstrual, follicular, periovulatory, luteal)
Number of subjects: 18
Study: 9443524

Group type: EXPERIMENTAL
Intervention: Intensive treatment with risperidone
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intensive treatment without risperidone
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard management
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intensive treatment groups (both with and without risperidone)
Number of subjects: 43
Study: 8407738

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg, three times a day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 3812051

Group type: EXPERIMENTAL
Intervention: 10% expanded tobacco
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 25% expanded tobacco
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both blends
Number of subjects: 24
Study: 30731492

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 3874

Group type: EXPERIMENTAL
Intervention: High SAMe-TT2-R2 score
Number of subjects: 3874

Group type: EXPERIMENTAL
Intervention: SAMe-TT2-R2 score
Number of subjects: 3874

Group type: EXPERIMENTAL
Intervention: High vs. low SAMe-TT2-R2 score
Number of subjects: 3874
Study: 28203684

Group type: EXPERIMENTAL
Intervention: Crushed ticagrelor tablets given orally
Number of subjects: 9

Group type: COMPARATOR
Intervention: Crushed ticagrelor tablets given sublingually
Number of subjects: 9
Study: 25440643

Group type: EXPERIMENTAL
Intervention: Vasopressin (1.8 U/h)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control (1.8 mL/h of normal saline)
Number of subjects: 92
Study: 23535252

Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 21636015

Group type: EXPERIMENTAL
Intervention: 25 g of glucose
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Elevated baseline blood glucose
Number of subjects: 56
Study: 19794940

Group type: COMPARATOR
Intervention: MLG treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MLG+IVTA treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: IVTA treatment
Number of subjects: 60
Study: 16920243

Group type: EXPERIMENTAL
Intervention: 19 commercially available and authority‐approved enzymes used in the food industry
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 12899896

Group type: EXPERIMENTAL
Intervention: Applied Relaxation (AR)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 22
Study: 10853908

Group type: EXPERIMENTAL
Intervention: Manipulative reduction followed by splinting the elbow in a flexed and supinated position for 2 days
Number of subjects: 64

Group type: COMPARATOR
Intervention: Manipulative reduction only
Number of subjects: 64
Study: 9089856

Group type: EXPERIMENTAL
Intervention: bupivacaine 1 mg plus sufentanil 5 micrograms plus epinephrine 25 micrograms
Number of subjects: 42

Group type: COMPARATOR
Intervention: bupivacaine 1 mg plus sufentanil 5 micrograms
Number of subjects: 42
Study: 8224289

Group type: EXPERIMENTAL
Intervention: Subconjunctival bupivacaine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 36
Study: 3544346

Group type: EXPERIMENTAL
Intervention: Non-operated patients with bilateral MCA trunk occlusion
Number of subjects: 9
Study: 31953725

Group type: EXPERIMENTAL
Intervention: 3D laparoscopic radical gastrectomy (3D-LG)
Number of subjects: 401

Group type: COMPARATOR
Intervention: 2D laparoscopic radical gastrectomy (2D-LG)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: 3D-LG
Number of subjects: 401

Group type: COMPARATOR
Intervention: 2D-LG
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Tumor diameter, pTNM stage, lymphovascular invasion
Number of subjects: 401
Study: 31182766

Group type: COMPARATOR
Intervention: Sorafenib treatment
Number of subjects: 1130
Study: 29256981

Group type: EXPERIMENTAL
Intervention: Excimer laser trephination
Number of subjects: 134

Group type: COMPARATOR
Intervention: Motor trephination (control)
Number of subjects: 134
Study: 26976495

Group type: EXPERIMENTAL
Intervention: Caffeine (20 mg/kg loading dose followed by 5 mg/kg daily maintenance until the 10th day of life)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (no caffeine treatment)
Number of subjects: 52
Study: 25029955

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.25 mg
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.5 mg
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 23146638

Group type: EXPERIMENTAL
Intervention: 2 cartridges of 2% lidocaine with 1:100,000 epinephrine via the IAN block
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Red-haired women with 2 RHC alleles
Number of subjects: 124

Group type: COMPARATOR
Intervention: Women with dark hair or women with 0 RHC alleles
Number of subjects: 124
Study: 20809193

Group type: EXPERIMENTAL
Intervention: Music therapy for noisiform tinnitus
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Imaging examinations
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Psychophysiological measurements
Number of subjects: 23
Study: 18055956

Group type: EXPERIMENTAL
Intervention: SSRIs plus CBT
Number of subjects: 208

Group type: COMPARATOR
Intervention: SSRIs alone
Number of subjects: 208
Study: 16338568

Group type: EXPERIMENTAL
Intervention: Additional counseling about potential intraoperative visual experience
Number of subjects: 219

Group type: COMPARATOR
Intervention: Routine preoperative counseling only (no additional counseling)
Number of subjects: 219
Study: 11806215

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 257

Group type: COMPARATOR
Intervention: Control (no antibiotics)
Number of subjects: 257
Study: 9552064

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 16 microg/kg
Number of subjects: 44

Group type: COMPARATOR
Intervention: High-dose cyclophosphamide (HDCTX) 6 g/m2 plus G-CSF 5 microg/kg
Number of subjects: 44
Study: 7939138

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) at an initial dose of 15 mg/week
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) at an initial dose of 25 mg/week
Number of subjects: 185
Study: 3373405

Group type: EXPERIMENTAL
Intervention: Indomethacin (0.1 mg/kg) administered intravenously every 24 hours for a total of three doses
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (saline solution) administered intravenously every 24 hours for a total of three doses
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Indomethacin treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline solution treatment
Number of subjects: 36
Study: 31849123

Group type: EXPERIMENTAL
Intervention: l-carnitine (LC) 2 g for 8 weeks
Number of subjects: 52
Study: 29844808

Group type: EXPERIMENTAL
Intervention: Anti-reflux treatment
Number of subjects: 136
Study: 26634616

Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 77

Group type: COMPARATOR
Intervention: Rumination
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control
Number of subjects: 77